D284TRK Maximo II CRT-D
Cardiac Resynchronization Therapy - Defibrillation (CRT-Defib)
D284TRK Maximo II CRT-D

Device Survival Probability


    1 yr 2 yr 3 yr 4 yr 5 yr 6 yr 7 yr at 91.0 mo    
% Excluding Normal Battery Depletion 100.0 99.7 99.4 98.9 98.7 98.7 98.7 98.7    
% Including Normal Battery Depletion 99.5 98.0 92.9 80.1 54.4 27.1 18.3 15.7    
#   12931 11677 10168 7757 4126 1426 502 117    
  • Including Normal Battery Depletion – This curve includes devices that have reached at least 80% of expected longevity. This curve is most representative of clinical performance and how long the device will last.
  • Excluding Normal Battery Depletion – This is the malfunction free survival curve.

Advisories For This Model

  • There are no advisories for this model.

Performance Notes For This Model

    • There are no performance notes for this model.

Product Characteristics

Generator Type CRT-Defib
Max. Delivered Energy 35 J
Connector Style CRT-D Style
Serial Number Prefix PZP
Mass 68 g
Volume 38 cc
Waveform Biphasic
Hide this content
CRT-D Style

Estimated Longevity

Charging Frequency 100% Pacing 50% Pacing 15% Pacing 100% Sensing
Monthly 3.2 3.8 4.4 4.7
Quarterly 4.4 5.5 6.8 7.5
Semi-annual 4.8 6.2 7.9 9.0

Longevity estimates based on the following device usage. Pacing Mode DDD; Atrial Lower Pacing Rate 60ppm; Ventricular Lower Pacing Rate 60ppm; Atrial Pulse Width 0.4ms; Ventricular Pulse Width 0.4ms; Atrial Pulse Amplitude 3V; Ventricular Pulse Amplitude 3V; Atrial Impedance 510ohms; Ventricle Impedance 510ohms; Atrial Sensing Rate 70bpm; Ventricle Sensing Rate 70bpm; EGM prestorage OFF; Integrated bi-ventricular pacing RV+LV; Left Ventricle Impedance 510ohms; Left Ventricular Pulse Width 0.4ms; Left Ventricular Pulse Amplitude 3V; Optivol ON; Atrial Fib percentage of time 0%; Charging frequency assumes maximum energy charge and includes therapy shocks and capacitor formation. Hide this content


Distribution Data

US Market Release2008-09-17
CE Approval Date2008-03-14
Registered USA Implants15249
Estimated Active USA Implants3096
Normal Battery Depletions3996
US Market Release2008-09-17
CE Approval Date2008-03-14
Estimated WW Distribution43528
Normal Battery Depletions4146

Malfunctions (USA)

Therapy Function Not Compromised 130
Electrical Component 6
Possible Early Battery Depletion 124
Therapy Function Compromised 5
Electrical Component 5

Malfunctions (WW)

Therapy Function Not Compromised 143
Battery 1
Electrical Component 7
Possible Early Battery Depletion 135
Therapy Function Compromised 8
Battery 1
Electrical Component 6
Possible Early Battery Depletion 1

EOS Indication

From the point that the RRT is set, the pacemaker will operate for approximately three months for typical pacemaker configurations during the normal operating life.


Recommended Replacement (RRT)

Battery voltage less than 2.63 V or Charge Time greater than 16 seconds.


Charge Time


Data as of April 11, 2019

www.medtronic.com/productperformance 651050